Both Pomegranate Extract and Genistein kill breast cancer cells, and they work even better together

Previous studies have demonstrated the anticancer effects of Pomegranate Extract and Genistein on cell lines from different cancers. Human breast cancer cell lines were exposed to both Pomegranate Extract and Genistein for 24 hours. Both Pomegranate Extract and Genistein significantly inhibited the growth of breast cancer cells. Both had significant cytotoxic effects on breast cancer cells ultimately causing the death of the cancer cells. Adding the two together significantly increased their ability to cause the death of breast cancer cells. The study was performed at Florida Atlantic University, Davie, Florida, and is published in the Winter 2005 issue of the Journal of Medicinal Food.

This is a much more useful study than is readily apparent. The COX-2 enzyme is active in many diseases. It is linked to decreased survival in cancer and increased ability of a tumor to metastasize because COX-2 and PGE2 allow the tumor to create its own transport system of blood vessels. COX-2 is active in cancers of the breast, colon, skin, bladder, esophagus, and pancreas. COX-2 plays a major role in inflammation and it also causes brain damage in Alzheimer's disease. COX-2 is involved with menstrual pain and other inflammation related conditions, but its best known role is in arthritis and joint damage.

Green Teas major Polyphenol, EGCG, strongly inhibits the development of prostate cancer in high risk men

Recent studies show that men with high grade prostate intraepithelial neoplasia (HG-PIN) will develop prostate cancer within one year. In this study 60 men with HG-PIN were placed on a Green Tea Polyphenol product consuming 200mg of Green Tea 3 times a day (with a EGCG content of 51.88% and a total Green Tea Polyphenol content of 75.7%) in a double-blind, placebo-controlled random study. After one year, 9 of the men placebo developed prostate cancer (a 30% incidence) while only one man on the Green Tea Polyphenols developed prostate cancer (3% incidence). The study is published in the January 15th, 2006 issue of the journal Cancer Research.